Global Primary Cells Market
Report Highlights
The global primary cells market should reach $1.9 billion by 2027 from $1.3 billion in 2022 at a compound annual growth rate (CAGR) of 9.0% for the forecast period of 2022 to 2027.
Report Includes
- 30 tables
- A comprehensive overview of the global market for primary cells
- Analyses of the global and regional market trends, with historic market revenue from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the upcoming market potential for primary cells, growth driving factors, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and revenue forecast for primary cells market in USD million terms, and corresponding market share analysis based on product type, product origin, application, end user, and region
- Discussion of the industry value chain analysis providing a systematic study of key intermediaries involved, with emphasis on manufacturers, suppliers, and major types of end users
- Identification of the companies that are best positioned to meet the demand for primary cells because of their proprietary technologies, strategic alliances, or other advantages
- Analysis of the vendor landscape based on their recent developments, financials, and segmental revenues
- Descriptive company profiles of the leading global players, including Charles River Laboratories, Lonza, Merck KGaA and Thermo Fisher Scientific
Report Scope
This report aims to provide a comprehensive study of the global market for primary cells, both in terms of quantitative and qualitative data, to help develop business/growth strategies, assess the market landscape, analyze their position in the current marketplace, and make informed business decisions regarding primary cells. Segmentation is based on biological source type, tissue source type, application, end user, and region.
Industry growth drivers, restraints, trends, and opportunities in the primary cells market are also discussed in detail. The report also provides information on the competitive landscape, elaborative company profiles, and the impact of COVID-19 on the market.
Frequently Asked Questions (FAQs)
• Since primary cells are more predictable indicators of human in vivo response than cell lines, it is becoming more acceptable tools in life sciences research, development of new drugs/therapies, and biological compounds (such as vaccines and therapeutic proteins) as well as in diverse applications where cell lines do not replicate the target biological system.
• Demand for primary cells is increasing globally, with a drive toward effective and efficient cell culture for basic research and biopharmaceutical research. Harmonized cell culture media and reagents and cell maintenance protocols are essential to support optimal, consistent primary cell growth and maintain the tissue-specific characteristics to ensure the experiment’s reliability and validity. Improvements in cell isolation and cryopreservation, optimized media, and reagents, and streamlined use protocols have contributed to the explosion of primary cell use in research programs globally.
• With growing investment in biomedical research, researchers around the globe are putting forward higher requirements for the quantity and quality of well annotated, properly preserved biological samples and biodata for pharmaceutical and diagnostic research. Cell biology laboratories constantly seek innovative new technologies to enhance their experimental workflows and help deliver on their promise to drive the next research breakthrough. Primary cells are more predictable indicators of human in vivo responses and therefore integrating primary cells into cell-based research programs can deliver biologically relevant and meaningful data because. Using primary cells has become more commonplace and, in some cases, has been mandated to receive data approval or further research funding.
• Cells are the foundation of any 3D model, and cell selection is a critical first step in the generation of any 3D model. Primary cells are increasingly used to build physiologically relevant 3D models to accelerate target identification and validation, investigation of mechanisms of action, and safety testing in drug discovery.
• Primary cell providers are using advanced processing and isolation techniques for procuring and handling donor tissues, improved enzymatic dissociation cocktails and techniques, and standardized cryopreservation procedures to provide an extensive array of high-quality primary cells and culture media to improve experimental reliability and validity. This has contributed to the explosion of primary cell use in research programs globally.
• Biologic therapies including cell and gene therapies are a new frontier in medicine. Primary cells are enabling advancements in gene editing, immunology, and cellular therapy leading to groundbreaking medical discoveries for life-threatening diseases.
The quantitative and qualitative assessment of the global primary cells market will help suppliers develop business/growth strategies, assess the market landscape, analyse their position in the current marketplace, and make informed business decisions regarding primary cells.
• Primary cell suppliers.
• Researchers.
• Primary cell start-ups.
• Academic and commercial research organizations.
• Consulting firms.
1. Thermo Fisher Scientific Inc.
2. Lonza.
3. Charles River Laboratories.
4. Merck KGaA.
5. Cell Biologics, Inc.
What key shifts/opportunities have been identified through the research?
o With a drive toward effective and efficient cell culture for basic research, drug discovery, and biopharmaceutical development, the global primary cell market is expected to grow at rapid rate through the forecast period.
o Enhancements in primary cell culture procurement, handling, and processing techniques, media formulation and cell maintenance protocols have also contributed to the explosion of primary cell use in research programs globally.
o Given the ethical concerns and cost associated with living animal testing, worldwide efforts are underway to reduce the number of animals and animal models for discovery and preclinical studies.
o The demand for HLA-typed primary cells is surging as researchers look to build ever-more predictive preclinical models for their personalized therapies.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2021 |
| Forecast period considered | 2022-2027 |
| Base year market size | $1.1 billion |
| Market size forecast | $1.9 billion |
| Growth rate | CAGR of 9.0% from 2022 to 2027 |
| Units considered | $ Millions |
| Segments covered | Biological Source Type, Tissue Source Type, End User, Application |
| Regions covered | North America, Europe, Asia Pacific, and Rest of the World (RoW) |
| Countries covered | United States, Canada, Germany, France, U.K., Italy, Rest of Europe (Spain, Switzerland, Denmark, Norway, Poland, Belgium, Austria, Netherlands, Sweden, Russia), China, Japan, India, Rest of Asia-Pacific (Australia, South Korea, New Zealand, Taiwan, Singapore, Malaysia, Thailand, Philippines, Indonesia), Latin America, Middle East and Africa |
| Key Market Drivers |
|
| Companies studied |
|